Dr. Lunning on Initial Treatment Considerations in CLL

Publication
Video
Supplements and Featured PublicationsMy Treatment Approach: Chronic Lymphocytic Leukemia
Volume 1
Issue 1

Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.

Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses initial treatment considerations in chronic lymphocytic leukemia (CLL).

Patients with CLL often present with asymptomatic disease that is identified with a routine complete blood count, Lunning explains.

To confirm a CLL diagnosis, patients typically undergo flow cytometry on peripheral blood, says Lunning. Afterward, a lymphocyte count, hemoglobin count, and platelet count should be conducted.

Additionally, patients should have a physical exam to identify splenomegaly, concerning adenopathy, or irregular lymph nodes, Lunning explains.

Richter’s transformation indicates a poorer prognosis and can significantly alter a patient’s treatment in the newly diagnosed or relapsed/refractory setting, concludes Lunning.

Related Videos
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Debu Tripathy, MD
Changchun Deng, MD, PhD
Joaquim Bellmunt, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Ramez Kouzy, MD, MD Anderson
Bernard A. Fox, PhD
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus